ORAU TEAM

Dose Reconstruction

Project for NIOSH

Oak Ridge Associated Universities I Dade Moeller & Associates I MJW Corporation

Page 1 of 22

Document Title:

Validation of DCAL Annual Dose Coefficients

Document Number: ORAUT-OTIB-0028

Revision: 02

Effective Date: 07/28/2008

Type of Document: OTIB

Supersedes: Rev 01 PC-1

Subject Expert(s): Thomas R. LaBone

Site Expert(s): N/A

Approval: Signature on File Approval Date: 07/21/2008

Thomas R. LaBone, Document Owner

Concurrence: Signature on File Concurrence Date: 07/18/2008

James P. Griffin, Deputy Project Director

Concurrence: Signature on File Concurrence Date: 07/23/2008

Kate Kimpan, Project Director

Approval: Signature on File Approval Date: 07/28/2008

James W. Neton, Associate Director for Science

 New Total Rewrite Revision Page Change

FOR DOCUMENTS MARKED AS A TOTAL REWRITE, REVISION, OR PAGE CHANGE, REPLACE THE PRIOR 

REVISION AND DISCARD / DESTROY ALL COPIES OF THE PRIOR REVISION
Document No. ORAUT-OTIB-0028 Revision No. 02 Effective Date: 07/28/2008 Page 2 of 22

PUBLICATION RECORD

EFFECTIVE 

DATE

REVISION 

NUMBER DESCRIPTION

02/14/2005 00 New technical information bulletin for the validation of thorium dose 

conversion factors to be used for internal dose assessment. First 

approved issue. Initiated by Elizabeth M. Brackett.

03/07/2005 01 Approved issue of Revision 01. Revised to add Th-228 values. 

Initiated by Elizabeth M. Brackett.

12/08/2006 01 PC-1 Approved page change revision to correct value in Table 3-2 on page 

6 in Section 3.0 and add a reference on page 7. No changes 

occurred as a result of formal internal and NIOSH review. There is 

no change to the assigned dose and no PER is required. Training 

required: As determined by the Task Manager. Initiated by Elizabeth 

M. Brackett. Approval:

James P. Griffin, Document Owner

Signature on File 11/29/2006

Kate Kimpan, Projector Director

Signature on File 12/01/2006

James W. Neton, Associate Director for Science

Brant A. Ulsh Signature on File for 12/08/2006

07/28/2008 02 Approved revision to document all dose calculations with the DCAL 

computer program. No further changes occurred as a result of 

formal internal and NIOSH review. Constitutes a total rewrite of the 

document. Training required: As determined by the Task Manager. 

Initiated by Thomas R. LaBone.
Document No. ORAUT-OTIB-0028 Revision No. 02 Effective Date: 07/28/2008 Page 3 of 22

TABLE OF CONTENTS

SECTION TITLE

Acronyms and Abbreviations ...............................................................................................................

PAGE

4

1.0 Introduction ..............................................................................................................................5

2.0 Purpose ...................................................................................................................................5

3.0 Background..............................................................................................................................5

4.0 Verification ...............................................................................................................................6

4.1 Discussion....................................................................................................................6

4.2 Results .........................................................................................................................7

5.0 Attributions and Annotations ....................................................................................................7

References ..........................................................................................................................................8

LIST OF TABLES

TABLE TITLE

4-1 Comparison of ICRP and DCAL dose coefficients for 131Te......................................................

PAGE

9

4-2 Comparison of ICRP and DCAL dose coefficients for 131mTe.................................................. 10

4-3 Comparison of ICRP and DCAL dose coefficients for 147Pr .................................................... 11

4-4 Comparison of ICRP and DCAL dose coefficients for 210Pb.................................................... 12

4-5 Comparison of ICRP and DCAL dose coefficients for 223Ra ................................................... 13

4-6 Comparison of ICRP and DCAL dose coefficients for 224Ra ................................................... 14

4-7 Comparison of ICRP and DCAL dose coefficients for 226Ra ................................................... 15

4-8 Comparison of ICRP and DCAL dose coefficients for 228Ac.................................................... 16

4-9 Comparison of ICRP and DCAL dose coefficients for 232U ..................................................... 17

4-10 Comparison of ICRP and DCAL dose coefficients for 233U ..................................................... 18

4-11 Comparison of ICRP and DCAL dose coefficients for 239U ..................................................... 19

4-12 Comparison of ICRP and DCAL dose coefficients for 228Th.................................................... 20

4-13 Comparison of ICRP and DCAL dose coefficients for 232Th.................................................... 21

4-14 Comparison of ICRP and DCAL dose coefficients for 234Th.................................................... 22
Document No. ORAUT-OTIB-0028 Revision No. 02 Effective Date: 07/28/2008 Page 4 of 22

ACRONYMS AND ABBREVIATIONS

Bq becquerel

DOE U.S. Department of Energy

EEOICPA Energy Employees Occupational Illness Compensation Program Act of 2000

IMBA Integrated Modules for Bioassay Analysis

ICRP International Commission on Radiological Protection

TIB technical information bulletin

U.S.C. United States Code

§ section or sections
Document No. ORAUT-OTIB-0028 Revision No. 02 Effective Date: 07/28/2008 Page 5 of 22

1.0

Technical information bulletins (TIBs) are not official determinations made by the National Institute for 

Occupational Safety and Health (NIOSH) but are rather general working documents that provide 

historic background information and guidance concerning the preparation of dose reconstructions at 

particular sites or categories of sites. They will be revised in the event additional relevant information 

is obtained about the affected site(s). TIBs may be used to assist NIOSH staff in the completion of 

individual dose reconstructions.

INTRODUCTION

In this document, the word “facility” is used as a general term for an area, building, or group of 

buildings that served a specific purpose at a site. It does not necessarily connote an “atomic weapons 

employer facility” or a “Department of Energy (DOE) facility” as defined in the Energy Employees 

Occupational Illness Compensation Program Act of 2000 [42 U.S.C. § 7384l(5) and (12)].

2.0

The Integrated Modules for Bioassay Analysis (IMBA) computer program is used for intake and dose 

assessments by the dose reconstructors. IMBA is known to calculate inaccurate organ doses for a 

small number of radionuclides. In these cases annual dose coefficients are calculated with the DCAL 

program (ORNL 2006). The protocol for when to use DCAL dose coefficients and verification of these 

dose coefficients is presented in this document.

PURPOSE

3.0

The calculations for International Commission on Radiological Protection (ICRP) Publication 68 dose 

coefficients (ICRP 1994) were performed by the ICRP Task Group on Dose Calculations with four 

independently written programs:

BACKGROUND

• IMIE, Ukrainian Radiation Protection Institute

• DCAL, United States DOE Oak Ridge National Laboratory

• DOSAGE, German Federal Office for Radiation Protection

• PLEIADES, United Kingdom Health Protection Agency

The results of these “first-tier” codes were compared as part of the quality assurance program for the 

ICRP Publication 68 (ICRP 1994) dose coefficients, which are available electronically on a compact 

disk (ICRP 2001). DCAL can be downloaded at no charge from the U.S. Environmental Protection 

Agency Web site and is the only one of the first-tier codes that is freely available to internal 

dosimetrists outside of the ICRP task group.

The various versions of IMBA – including the IMBA Expert ORAU-Edition – are considered to 

constitute a second-tier dosimetry code, and 50-year committed dose coefficients from it were 

compared to those from PLEIADES by the authors of IMBA as part of their quality assurance 

program. The results of these comparisons are given in Appendix C to the IMBA user manual. The 

vast majority of the committed organ dose coefficients that are calculated with IMBA agree with those 

from PLEIADES to within ±1%, but there are a small number of cases where the difference is larger. 

These differences can typically be attributed to the fact that IMBA does not accurately account for the 

shared biokinetics of radioactive progeny in the body after intake of the parent radionuclide. 

Uranium-232 is an example of such a radionuclide. An unrelated issue is that IMBA does not 

calculate doses properly for some short-lived radionuclides after chronic intakes. These radionuclides 

include 147Pr, 228Ac, and 239U.
Document No. ORAUT-OTIB-0028 Revision No. 02 Effective Date: 07/28/2008 Page 6 of 22

4.0

4.1 Discussion

VERIFICATION

Annual organ dose coefficients from IMBA are considered acceptable if the committed organ dose 

coefficients that are calculated with IMBA agree with the committed organ dose coefficients from 

PLEIADES to within ±10% (as discussed in Appendix C of the IMBA user documentation). Note that 

all comparisons are performed with 50-year committed organ dose coefficients and it is implicitly 

assumed that acceptable agreement between these dose coefficients means that the annual organ 

dose coefficients from IMBA are acceptable. In cases where there a comparison of IMBA and 

PLEIADES is not available (e.g., 233U), committed organ dose coefficients from IMBA are to be 

compared to the committed organ dose coefficients from the ICRP compact disk (ICRP 2001), which

is an electronic version of the dose coefficients published in Publication 68 (ICRP 1994). Dose 

coefficients from IMBA are considered acceptable if these dose coefficients agree with the ICRP 

coefficients to within ±10%.

In general, DCAL was used to calculate organ dose coefficients in cases where the committed organ 

dose coefficients that are calculated with IMBA have differences greater than ±10% in comparison to 

those that were calculated with PLEIADES or those from the ICRP compact disk (ICRP 2001). The 

committed organ dose coefficients that were calculated with DCAL were compared to those from the 

ICRP as part of the quality assurance of the DCAL organ dose coefficients. The DCAL organ dose 

coefficients are to be used as long as they agree with the ICRP dose coefficients better than those 

from IMBA do; that is, no acceptable cutoff is proposed for comparison of DCAL with the ICRP 

coefficients. Note that if one or more committed organ dose coefficients for a radioactive material 

(radionuclide, intake mode, solubility type, etc.) that are calculated with IMBA have unacceptably large 

errors, DCAL organ dose coefficients are to be adopted for all organs for that material. In other 

words, all of the organ dose coefficients for a given radioactive material will usually be from either 

from IMBA or DCAL rather than a mixture of the two.

The comparisons of committed organ dose coefficients from DCAL and the ICRP compact disk (ICRP 

2001) are documented in this technical bulletin. The annual organ dose coefficients that are 

calculated with DCAL are used to construct input tables for the acute/chronic intake tool CADW. 

Dose coefficient calculations that cannot be performed with CADW are to be handled on a case-bycase basis as directed by the Principal Internal Dosimetrist. It is important to note that IMBA will 

calculate the correct intake for a given bioassay dataset even though the resultant dose might have 

unacceptably large errors.

The relevant DCAL output file for a particular radionuclide is the dose rate file (HRT file extension). 

Organ doses for any period of interest after acute or chronic intakes can be derived from an 

appropriate integration of the organ dose coefficients in this file. These integrations and other 

necessary manipulations of the data were performed with a program written in the R programming 

language. All input parameters that were used in DCAL are those recommended by the ICRP1

• Tellurium-131 and -131m

. 

Annual organ equivalent dose coefficients for all intake modes and solubility types were calculated 

with DCAL for an acute intake of 1 Bq at time zero and for a chronic intake of 1 Bq over 1 year for the 

following radionuclides:

• Praseodymium-147

• Lead-210

• Radium-223, -224, and -226

 1 The systemic biokinetic model for actinium in DCAL is not the default ICRP biokinetic model for actinium. Therefore, the 

DCAL actinium model was changed to the default ICRP model for these calculations.
Document No. ORAUT-OTIB-0028 Revision No. 02 Effective Date: 07/28/2008 Page 7 of 22

• Actinium-228

• Uranium-232, -233, and -239

• Thorium-228, -232, and -234

4.2 Results

The results from DCAL generally agree with those from the ICRP compact disk (ICRP 2001) to within 

a few percent. The minor differences can be attributed in part to the number of significant digits (two) 

with which the ICRP organ dose coefficients are reported. Larger differences on the order of 10% 

were observed in isolated cases (224Ra ingestion for example). These differences are considered to 

be acceptable because the DCAL calculations are considered to be correct (Eckerman 2008) and the 

differences are considerably smaller than the equivalent differences between the IMBA and ICRP

dose coefficients. Therefore, the agreement between DCAL and ICRP organ dose coefficients 

evident in Tables 4-1 through 4-14 is considered to provide verification that the DCAL calculations are 

correct. 

5.0

No Attributions and Annotations are needed because all figure calculations and technical content 

were performed and authored by Thomas LaBone.

ATTRIBUTIONS AND ANNOTATIONS
Document No. ORAUT-OTIB-0028 Revision No. 02 Effective Date: 07/28/2008 Page 8 of 22

REFERENCES

Eckerman, K. F., R. W. Leggett, M. Cristy, C. B. Nelson, J. C. Ryman, A. L. Sjoreen, and R. C. Ward, 

2006, User’s Guide to the DCAL System, ORNL/TM-2001/190, UT-Battelle, Oak Ridge 

National Laboratory, Oak Ridge, Tennessee, August. [SRDB Ref ID: 43944]

LaBone, T.R., 2008, “DCF for Ra-224,” documented communication with K. F. Eckerman (ORNL), 

Oak Ridge Associated Universities Team, Oak Ridge, Tennessee, January 28, 2008. [SRDB 

Ref ID: 44041]

ICRP (International Commission on Radiological Protection), 1994, Dose Coefficients for Intakes of 

Radionuclides by Workers, Publication 68, Pergamon Press, Oxford, England.

ICRP (International Commission on Radiological Protection), 2001, ICRP Database of Dose 

Coefficients: Workers and Members of the Public, Version 2.0.1, Pergamon Press, Oxford, 

England.
Document No. ORAUT-OTIB-0028 Revision No. 02 Effective Date: 07/28/2008 Page 

9 of 22

Table 4-1. Comparison of ICRP and DCAL dose coefficients for 131Te. Inhalation type V Inhalation type F Inhalation type M Ingestion: f1 = 0.3

ICRP DCAL Ratio ICRP DCAL Ratio ICRP DCAL Ratio ICRP DCAL Ratio

Adrenals 3.1E-12 3.15E-12 0.98 1.4E-12 1.37E-12 1.02 7.6E-13 7.67E-13 0.99 1.5E-12 1.55E-12 0.97

Bladder wall 8.2E-12 8.26E-12 0.99 3.5E-12 3.50E-12 1.00 1.2E-12 1.17E-12 1.03 2.4E-12 2.37E-12 1.01

Bone surface 3.4E-12 3.45E-12 0.99 1.7E-12 1.72E-12 0.99 8.4E-13 8.78E-13 0.96 8.2E-13 8.62E-13 0.95

Brain 2.9E-12 2.89E-12 1.00 1.5E-12 1.52E-12 0.99 7.1E-13 7.14E-13 0.99 3.9E-13 3.88E-13 1.01

Breast 2.9E-12 2.89E-12 1.00 1.2E-12 1.19E-12 1.01 5.6E-13 5.63E-13 0.99 5.1E-13 5.14E-13 0.99

St wall 3.1E-11 3.07E-11 1.01 5.6E-11 5.59E-11 1.00 9.1E-11 9.08E-11 1.00 3.3E-10 3.29E-10 1.00

Si wall 1.1E-11 1.12E-11 0.98 1.8E-11 1.78E-11 1.01 2.8E-11 2.77E-11 1.01 1.0E-10 1.00E-10 1.00

ULI wall 6.0E-12 5.99E-12 1.00 6.4E-12 6.41E-12 1.00 8.5E-12 8.58E-12 0.99 3.0E-11 3.06E-11 0.98

LLI wall 3.2E-12 3.23E-12 0.99 1.9E-12 1.90E-12 1.00 1.5E-12 1.50E-12 1.00 4.8E-12 4.87E-12 0.99

Kidneys 3.1E-12 3.13E-12 0.99 1.4E-12 1.43E-12 0.98 6.7E-13 6.79E-13 0.99 1.7E-12 1.73E-12 0.98

Liver 3.0E-12 3.03E-12 0.99 1.3E-12 1.28E-12 1.02 6.0E-13 6.08E-13 0.99 1.1E-12 1.09E-12 1.01

Muscle 3.0E-12 3.05E-12 0.98 1.6E-12 1.57E-12 1.02 8.6E-13 8.68E-13 0.99 1.0E-12 1.04E-12 0.96

Ovaries 2.9E-12 2.97E-12 0.98 1.5E-12 1.48E-12 1.01 8.2E-13 8.29E-13 0.99 2.5E-12 2.54E-12 0.98

Pancreas 3.4E-12 3.42E-12 0.99 2.0E-12 2.01E-12 1.00 1.7E-12 1.76E-12 0.97 5.3E-12 5.33E-12 0.99

Red marrow 3.2E-12 3.17E-12 1.01 1.5E-12 1.53E-12 0.98 7.7E-13 7.78E-13 0.99 1.1E-12 1.06E-12 1.04

ET1 1.7E-08 1.71E-08 0.99 5.8E-08 5.79E-08 1.00 5.8E-08 5.79E-08 1.00 4.2E-13 4.22E-13 1.00

ET2 2.1E-10 2.14E-10 0.98 4.5E-10 4.53E-10 0.99 6.9E-10 6.92E-10 1.00 4.2E-13 4.22E-13 1.00

LNet 3.7E-11 3.68E-11 1.01 1.0E-10 1.04E-10 0.96 1.1E-10 1.14E-10 0.96 4.2E-13 4.22E-13 1.00

Lungs 1.6E-10 1.62E-10 0.99 2.5E-11 2.45E-11 1.02 8.7E-11 8.72E-11 1.00 8.0E-13 8.09E-13 0.99

LNth 4.3E-12 4.35E-12 0.99 1.6E-12 1.60E-12 1.00 1.6E-12 1.57E-12 1.02 8.0E-13 8.09E-13 0.99

Skin 2.6E-12 2.63E-12 0.99 1.2E-12 1.19E-12 1.01 4.4E-13 4.45E-13 0.99 4.9E-13 4.86E-13 1.01

Spleen 3.2E-12 3.17E-12 1.01 1.6E-12 1.65E-12 0.97 1.2E-12 1.22E-12 0.98 3.4E-12 3.42E-12 0.99

Testes 2.6E-12 2.60E-12 1.00 1.0E-12 1.04E-12 0.96 1.9E-13 1.91E-13 0.99 2.9E-13 2.86E-13 1.01

Thymus 3.4E-12 3.39E-12 1.00 1.7E-12 1.69E-12 1.01 1.0E-12 1.05E-12 0.95 6.2E-13 6.26E-13 0.99

Thyroid 8.4E-10 8.44E-10 1.00 4.4E-10 4.45E-10 0.99 3.9E-10 3.91E-10 1.00 8.9E-10 8.91E-10 1.00

Uterus 3.0E-12 2.97E-12 1.01 1.4E-12 1.44E-12 0.97 7.2E-13 7.27E-13 0.99 2.1E-12 2.16E-12 0.97

Effective dose 6.8E-11 6.79E-11 1.00 4.6E-11 4.61E-11 1.00 6.1E-11 6.08E-11 1.00 8.7E-11 8.75E-11 0.99
Document No. ORAUT-OTIB-0028 Revision No. 02 Effective Date: 07/28/2008 Page 10 of 22

Table 4-2. Comparison of ICRP and DCAL dose coefficients for 131mTe. Inhalation type V Inhalation type F Inhalation type M Ingestion: f1 = 0.3

ICRP DCAL Ratio ICRP DCAL Ratio ICRP DCAL Ratio ICRP DCAL Ratio

Adrenals 2.2E-10 2.24E-10 0.98 1.0E-10 1.02E-10 0.98 8.5E-11 8.56E-11 0.99 1.2E-10 1.24E-10 0.97

Bladder wall 7.1E-10 7.20E-10 0.99 3.2E-10 3.25E-10 0.98 1.9E-10 1.97E-10 0.96 4.3E-10 4.35E-10 0.99

Bone surface 1.3E-09 1.34E-09 0.97 5.7E-10 5.76E-10 0.99 2.7E-10 2.78E-10 0.97 5.0E-10 5.03E-10 0.99

Brain 1.7E-10 1.72E-10 0.99 9.7E-11 9.77E-11 0.99 6.1E-11 6.13E-11 1.00 5.6E-11 5.66E-11 0.99

Breast 1.4E-10 1.41E-10 0.99 6.6E-11 6.68E-11 0.99 6.4E-11 6.45E-11 0.99 5.7E-11 5.71E-11 1.00

St wall 2.4E-10 2.40E-10 1.00 2.0E-10 1.98E-10 1.01 2.9E-10 2.95E-10 0.98 6.7E-10 6.73E-10 1.00

Si wall 3.6E-10 3.63E-10 0.99 3.5E-10 3.51E-10 1.00 5.4E-10 5.46E-10 0.99 1.3E-09 1.36E-09 0.96

ULI wall 9.4E-10 9.46E-10 0.99 1.0E-09 1.06E-09 0.94 1.7E-09 1.76E-09 0.97 4.4E-09 4.43E-09 0.99

LLI wall 1.6E-09 1.59E-09 1.01 1.8E-09 1.86E-09 0.97 3.1E-09 3.14E-09 0.99 7.9E-09 7.92E-09 1.00

Kidneys 5.9E-10 5.91E-10 1.00 2.6E-10 2.59E-10 1.00 1.5E-10 1.49E-10 1.01 3.0E-10 3.00E-10 1.00

Liver 1.9E-10 1.90E-10 1.00 9.0E-11 9.15E-11 0.98 8.3E-11 8.46E-11 0.98 1.3E-10 1.35E-10 0.96

Muscle 1.9E-10 1.92E-10 0.99 1.1E-10 1.13E-10 0.97 9.6E-11 9.72E-11 0.99 1.4E-10 1.40E-10 1.00

Ovaries 3.1E-10 3.12E-10 0.99 2.3E-10 2.29E-10 1.00 2.9E-10 2.96E-10 0.98 7.2E-10 7.28E-10 0.99

Pancreas 2.1E-10 2.16E-10 0.97 1.1E-10 1.08E-10 1.02 9.8E-11 9.94E-11 0.99 1.8E-10 1.79E-10 1.01

Red marrow 4.4E-10 4.45E-10 0.99 2.1E-10 2.16E-10 0.97 1.5E-10 1.51E-10 0.99 2.6E-10 2.66E-10 0.98

ET1 4.8E-07 4.87E-07 0.99 1.6E-06 1.65E-06 0.97 1.6E-06 1.65E-06 0.97 6.2E-11 6.27E-11 0.99

ET2 2.6E-09 2.68E-09 0.97 8.1E-09 8.22E-09 0.99 8.7E-09 8.85E-09 0.98 6.2E-11 6.27E-11 0.99

LNet 2.4E-09 2.49E-09 0.96 7.7E-09 7.84E-09 0.98 7.7E-09 7.89E-09 0.98 6.2E-11 6.27E-11 0.99

Lungs 3.8E-10 3.89E-10 0.98 1.2E-10 1.21E-10 0.99 3.6E-09 3.65E-09 0.99 7.3E-11 7.42E-11 0.98

LNth 1.8E-10 1.84E-10 0.98 9.1E-11 9.23E-11 0.99 1.9E-10 1.91E-10 0.99 7.3E-11 7.42E-11 0.98

Skin 1.4E-10 1.39E-10 1.01 7.1E-11 7.15E-11 0.99 5.1E-11 5.13E-11 0.99 7.4E-11 7.48E-11 0.99

Spleen 1.9E-10 1.95E-10 0.97 9.3E-11 9.43E-11 0.99 8.3E-11 8.40E-11 0.99 1.4E-10 1.42E-10 0.99

Testes 1.6E-10 1.66E-10 0.96 7.5E-11 7.68E-11 0.98 4.9E-11 4.97E-11 0.99 1.1E-10 1.12E-10 0.98

Thymus 1.8E-10 1.88E-10 0.96 1.1E-10 1.08E-10 1.02 1.0E-10 1.01E-10 0.99 6.7E-11 6.84E-11 0.98

Thyroid 4.0E-08 4.00E-08 1.00 1.7E-08 1.72E-08 0.99 9.5E-09 9.47E-09 1.00 1.8E-08 1.85E-08 0.97

Uterus 2.5E-10 2.56E-10 0.98 1.5E-10 1.53E-10 0.98 1.6E-10 1.58E-10 1.01 3.7E-10 3.80E-10 0.97

Effective dose 2.4E-09 2.42E-09 0.99 1.2E-09 1.18E-09 1.02 1.6E-09 1.60E-09 1.00 1.9E-09 1.95E-09 0.97
Document No. ORAUT-OTIB-0028 Revision No. 02 Effective Date: 07/28/2008 Page 11 of 22

Table 4-3. Comparison of ICRP and DCAL dose coefficients for 147Pr.

Inhalation type M Inhalation type S Ingestion: f1 = 0.0005

ICRP DCAL Ratio ICRP DCAL Ratio ICRP DCAL Ratio

Adrenals 6.3E-13 6.37E-13 0.99 5.8E-13 5.868E-13 0.99 1.7E-12 1.67E-12 1.02

Bladder wall 2.2E-13 2.17E-13 1.01 1.4E-13 1.395E-13 1.00 5.4E-13 5.41E-13 1.00

Bone surface 1.2E-12 1.21E-12 0.99 6.5E-13 6.654E-13 0.98 4.9E-13 5.02E-13 0.98

Brain 6.0E-13 6.03E-13 0.99 5.5E-13 5.547E-13 0.99 1.1E-14 1.02E-14 1.07

Breast 4.4E-13 4.41E-13 1.00 4.0E-13 4.020E-13 1.00 4.1E-13 4.02E-13 1.02

St wall 5.6E-11 5.65E-11 0.99 5.8E-11 5.857E-11 0.99 2.5E-10 2.53E-10 0.99

Si wall 1.1E-11 1.08E-11 1.02 1.1E-11 1.114E-11 0.99 4.7E-11 4.75E-11 0.99

ULI wall 4.0E-12 4.06E-12 0.98 4.1E-12 4.155E-12 0.99 1.4E-11 1.45E-11 0.97

LLI wall 4.9E-12 4.92E-12 1.00 5.1E-12 5.103E-12 1.00 1.3E-11 1.28E-11 1.01

Kidneys 6.8E-13 6.81E-13 1.00 4.8E-13 4.849E-13 0.99 1.7E-12 1.74E-12 0.98

Liver 1.3E-12 1.26E-12 1.03 4.3E-13 4.335E-13 0.99 1.0E-12 1.02E-12 0.98

Muscle 7.4E-13 7.42E-13 1.00 6.9E-13 6.992E-13 0.99 7.8E-13 7.80E-13 1.00

Ovaries 5.6E-13 5.66E-13 0.99 5.2E-13 5.215E-13 1.00 2.1E-12 2.08E-12 1.01

Pancreas 1.7E-12 1.70E-12 1.00 1.7E-12 1.693E-12 1.00 6.5E-12 6.64E-12 0.98

Red marrow 7.1E-13 7.11E-13 1.00 5.7E-13 5.716E-13 1.00 7.9E-13 7.91E-13 1.00

ET1 3.0E-08 3.14E-08 0.95 3.0E-08 3.145E-08 0.95 4.4E-14 4.26E-14 1.03

ET2 5.6E-10 5.80E-10 0.96 5.8E-10 5.990E-10 0.97 4.4E-14 4.26E-14 1.03

LNet 1.4E-10 1.43E-10 0.98 1.4E-10 1.448E-10 0.97 4.4E-14 4.26E-14 1.03

Lungs 5.2E-11 5.37E-11 0.97 5.6E-11 5.798E-11 0.97 6.5E-13 6.52E-13 1.00

LNth 1.3E-12 1.33E-12 0.98 1.4E-12 1.439E-12 0.97 6.5E-13 6.52E-13 1.00

Skin 3.5E-13 3.48E-13 1.01 3.0E-13 3.022E-13 0.99 3.1E-13 3.11E-13 1.00

Spleen 1.1E-12 1.12E-12 0.98 1.1E-12 1.100E-12 1.00 4.0E-12 4.10E-12 0.98

Testes 8.9E-14 8.89E-14 1.00 3.4E-14 3.315E-14 1.03 1.2E-13 1.21E-13 0.99

Thymus 8.9E-13 8.91E-13 1.00 8.5E-13 8.525E-13 1.00 3.0E-13 2.95E-13 1.02

Thyroid 6.6E-13 6.60E-13 1.00 6.1E-13 6.121E-13 1.00 4.4E-14 4.26E-14 1.03

Uterus 4.6E-13 4.62E-13 1.00 4.1E-13 4.137E-13 0.99 1.7E-12 1.69E-12 1.00

Effective dose 2.9E-11 2.94E-11 0.99 3.0E-11 3.060E-11 0.98 3.3E-11 3.28E-11 1.01
Document No. ORAUT-OTIB-0028 Revision No. 02 Effective Date: 07/28/2008 Page 12 of 22

Table 4-4. Comparison of ICRP and DCAL dose coefficients for 210Pb.

Inhalation type F Ingestion: f1 = 0.2

ICRP DCAL Ratio ICRP DCAL Ratio

Adrenals 1.4E-07 1.42E-07 0.99 8.6E-08 8.81E-08 0.98

Bladder wall 1.4E-07 1.43E-07 0.98 8.7E-08 8.89E-08 0.98

Bone surface 3.6E-05 3.63E-05 0.99 2.3E-05 2.26E-05 1.02

Brain 1.4E-07 1.42E-07 0.99 8.6E-08 8.81E-08 0.98

Breast 1.4E-07 1.41E-07 0.99 8.6E-08 8.81E-08 0.98

St wall 1.4E-07 1.41E-07 0.99 8.6E-08 8.81E-08 0.98

Si wall 1.4E-07 1.42E-07 0.99 8.6E-08 8.82E-08 0.97

ULI wall 1.4E-07 1.45E-07 0.97 8.9E-08 9.11E-08 0.98

LLI wall 1.5E-07 1.52E-07 0.99 9.7E-08 9.88E-08 0.98

Kidneys 5.9E-06 5.99E-06 0.99 3.7E-06 3.73E-06 0.99

Liver 3.0E-06 3.09E-06 0.97 1.9E-06 1.92E-06 0.99

Muscle 1.4E-07 1.41E-07 0.99 8.6E-08 8.81E-08 0.98

Ovaries 1.4E-07 1.41E-07 0.99 8.6E-08 8.81E-08 0.98

Pancreas 1.4E-07 1.41E-07 0.99 8.6E-08 8.81E-08 0.98

Red marrow 4.0E-06 3.99E-06 1.00 2.5E-06 2.48E-06 1.01

ET1 3.7E-07 3.74E-07 0.99 8.6E-08 8.81E-08 0.98

ET2 1.4E-07 1.42E-07 0.99 8.6E-08 8.81E-08 0.98

LNet 1.4E-07 1.42E-07 0.99 8.6E-08 8.81E-08 0.98

Lungs 1.4E-07 1.41E-07 0.99 8.6E-08 8.81E-08 0.98

LNth 1.4E-07 1.41E-07 0.99 8.6E-08 8.81E-08 0.98

Skin 1.4E-07 1.41E-07 0.99 8.6E-08 8.81E-08 0.98

Spleen 4.4E-06 4.51E-06 0.98 2.8E-06 2.81E-06 1.00

Testes 1.4E-07 1.41E-07 0.99 8.6E-08 8.81E-08 0.98

Thymus 1.4E-07 1.41E-07 0.99 8.6E-08 8.81E-08 0.98

Thyroid 1.4E-07 1.41E-07 0.99 8.6E-08 8.81E-08 0.98

Uterus 1.4E-07 1.41E-07 0.99 8.6E-08 8.81E-08 0.98

Effective dose 1.1E-06 1.12E-06 0.99 6.8E-07 6.96E-07 0.98
Document No. ORAUT-OTIB-0028 Revision No. 02 Effective Date: 07/28/2008 Page 13 of 22

Table 4-5. Comparison of ICRP and DCAL dose coefficients for 

223Ra

.

Inhalation type M Ingestion: f1 = 0.2

ICRP DCAL Ratio ICRP DCAL Ratio

Adrenals 7.1E-09 7.20E-09 0.99 1.3E-08 1.28E-08 1.02

Bladder wall 7.1E-09 7.29E-09 0.97 1.3E-08 1.30E-08 1.00

Bone surface 1.7E-06 1.66E-06 1.02 2.9E-06 2.94E-06 0.99

Brain 7.0E-09 7.16E-09 0.98 1.3E-08 1.27E-08 1.02

Breast 7.0E-09 7.19E-09 0.97 1.3E-08 1.27E-08 1.02

St wall 9.4E-09 9.72E-09 0.97 1.8E-08 1.88E-08 0.96

Si wall 1.2E-08 1.26E-08 0.95 2.5E-08 2.61E-08 0.96

ULI wall 4.7E-08 5.06E-08 0.93 1.1E-07 1.14E-07 0.96

LLI wall 1.2E-07 1.28E-07 0.94 2.7E-07 2.95E-07 0.92

Kidneys 1.0E-08 9.85E-09 1.02 1.8E-08 1.78E-08 1.01

Liver 8.1E-08 8.22E-08 0.99 1.4E-07 1.46E-07 0.96

Muscle 7.0E-09 7.19E-09 0.97 1.3E-08 1.28E-08 1.02

Ovaries 6.9E-09 7.28E-09 0.95 1.2E-08 1.30E-08 0.92

Pancreas 7.1E-09 7.19E-09 0.99 1.3E-08 1.28E-08 1.02

Red marrow 1.6E-07 1.59E-07 1.01 2.8E-07 2.83E-07 0.99

ET1 6.0E-03 6.07E-03 0.99 1.3E-08 1.27E-08 1.02

ET2 6.0E-06 6.09E-06 0.99 1.3E-08 1.27E-08 1.02

LNet 3.0E-08 3.01E-08 1.00 1.3E-08 1.27E-08 1.02

Lungs 4.7E-05 4.66E-05 1.01 1.3E-08 1.27E-08 1.02

LNth 2.0E-07 1.99E-07 1.01 1.3E-08 1.27E-08 1.02

Skin 7.0E-09 7.16E-09 0.98 1.3E-08 1.27E-08 1.02

Spleen 6.9E-09 7.19E-09 0.96 1.2E-08 1.28E-08 0.94

Testes 6.8E-09 7.16E-09 0.95 1.2E-08 1.28E-08 0.94

Thymus 7.1E-09 7.20E-09 0.99 1.3E-08 1.27E-08 1.02

Thyroid 7.0E-09 7.17E-09 0.98 1.3E-08 1.27E-08 1.02

Uterus 7.1E-09 7.21E-09 0.98 1.3E-08 1.29E-08 1.01

Effective dose 5.7E-06 5.65E-06 1.01 1.0E-07 1.04E-07 0.96
Document No. ORAUT-OTIB-0028 Revision No. 02 Effective Date: 07/28/2008 Page 14 of 22

Table 4-6. Comparison of ICRP and DCAL dose coefficients for 224Ra.

Inhalation type M Ingestion: f1 = 0.2

ICRP DCAL Ratio ICRP DCAL Ratio

Adrenals 5.7E-09 5.37E-09 1.06 1.1E-08 9.77E-09 1.13

Bladder wall 5.8E-09 5.48E-09 1.06 1.1E-08 1.01E-08 1.09

Bone surface 9.5E-07 9.49E-07 1.00 1.7E-06 1.73E-06 0.98

Brain 5.6E-09 5.31E-09 1.05 1.1E-08 9.71E-09 1.13

Breast 5.7E-09 5.34E-09 1.07 1.1E-08 9.71E-09 1.13

St wall 7.4E-09 7.12E-09 1.04 1.5E-08 1.41E-08 1.06

Si wall 8.7E-09 9.27E-09 0.94 1.8E-08 1.96E-08 0.92

ULI wall 3.6E-08 3.63E-08 0.99 8.3E-08 8.35E-08 0.99

LLI wall 9.3E-08 9.34E-08 1.00 2.2E-07 2.20E-07 1.00

Kidneys 2.3E-08 2.14E-08 1.07 4.5E-08 4.05E-08 1.11

Liver 3.0E-08 2.95E-08 1.02 5.6E-08 5.42E-08 1.03

Muscle 5.7E-09 5.36E-09 1.06 1.1E-08 9.79E-09 1.12

Ovaries 5.8E-09 5.62E-09 1.03 1.1E-08 1.05E-08 1.05

Pancreas 5.7E-09 5.36E-09 1.06 1.1E-08 9.78E-09 1.12

Red marrow 9.1E-08 9.08E-08 1.00 1.7E-07 1.66E-07 1.02

ET1 3.9E-03 0.00391 1.00 1.1E-08 9.71E-09 1.13

ET2 2.1E-06 2.02E-06 1.04 1.1E-08 9.71E-09 1.13

LNet 1.3E-08 1.29E-08 1.01 1.1E-08 9.71E-09 1.13

Lungs 2.0E-05 1.87E-05 1.07 1.1E-08 9.72E-09 1.13

LNth 3.0E-08 2.89E-08 1.04 1.1E-08 9.72E-09 1.13

Skin 5.6E-09 5.31E-09 1.05 1.1E-08 9.73E-09 1.13

Spleen 5.6E-09 5.35E-09 1.05 1.1E-08 9.77E-09 1.13

Testes 5.5E-09 5.32E-09 1.03 1.0E-08 9.78E-09 1.02

Thymus 5.7E-09 5.37E-09 1.06 1.1E-08 9.71E-09 1.13

Thyroid 5.6E-09 5.33E-09 1.05 1.1E-08 9.71E-09 1.13

Uterus 5.7E-09 5.42E-09 1.05 1.1E-08 1.00E-08 1.10

Effective dose 2.4E-06 2.27E-06 1.06 6.5E-08 6.45E-08 1.01
Document No. ORAUT-OTIB-0028 Revision No. 02 Effective Date: 07/28/2008 Page 15 of 22

Table 4-7. Comparison of ICRP and DCAL dose coefficients for 226Ra.

Inhalation type M Ingestion: f1 = 0.2

ICRP DCALRatio ICRP DCAL Ratio

Adrenals 3.0E-08 2.98E-08 1.01 4.1E-08 4.10E-08 1.00

Bladder wall 2.9E-08 2.91E-08 1.00 4.0E-08 4.00E-08 1.00

Bone surface 9.0E-06 9.06E-06 0.99 1.2E-05 1.25E-05 0.96

Brain 2.9E-08 2.96E-08 0.98 4.1E-08 4.07E-08 1.01

Breast 2.9E-08 2.90E-08 1.00 4.0E-08 3.98E-08 1.00

St wall 2.9E-08 2.95E-08 0.98 4.1E-08 4.11E-08 1.00

Si wall 3.0E-08 3.04E-08 0.99 4.2E-08 4.31E-08 0.98

ULI wall 4.1E-08 4.18E-08 0.98 6.4E-08 6.67E-08 0.96

LLI wall 8.0E-08 8.25E-08 0.97 1.5E-07 1.52E-07 0.99

Kidneys 4.3E-08 4.32E-08 1.00 5.9E-08 5.95E-08 0.99

Liver 1.3E-07 1.30E-07 1.00 1.8E-07 1.79E-07 1.01

Muscle 2.9E-08 2.93E-08 0.99 4.0E-08 4.03E-08 0.99

Ovaries 2.9E-08 2.95E-08 0.98 4.1E-08 4.07E-08 1.01

Pancreas 2.9E-08 2.93E-08 0.99 4.0E-08 4.03E-08 0.99

Red marrow 6.4E-07 6.37E-07 1.01 8.7E-07 8.76E-07 0.99

ET1 6.4E-06 0.000536 0.01 4.0E-08 4.02E-08 0.99

ET2 1.3E-05 1.26E-05 1.03 4.0E-08 4.02E-08 0.99

LNet 5.7E-07 5.72E-07 1.00 4.0E-08 4.02E-08 0.99

Lungs 1.7E-05 1.66E-05 1.034.0E-08 4.02E-08 0.99

LNth 2.5E-06 2.55E-06 0.98 4.0E-08 4.02E-08 0.99

Skin 2.9E-08 2.91E-08 1.00 4.0E-08 4.00E-08 1.00

Spleen 3.9E-08 3.91E-08 1.00 5.3E-08 5.38E-08 0.99

Testes 2.9E-08 2.89E-08 1.00 4.0E-08 3.98E-08 1.00

Thymus 2.9E-08 2.91E-081.00 4.0E-08 4.00E-08 1.00

Thyroid 2.9E-08 2.92E-08 0.99 4.0E-08 4.02E-08 0.99

Uterus 2.9E-08 2.92E-08 0.99 4.0E-08 4.02E-08 1.00

Effective dose 2.2E-06 2.18E-06 1.01 2.8E-07 2.80E-07 1.00
Document No. ORAUT-OTIB-0028 Revision No. 02 Effective Date: 07/28/2008 Page 16 of 22

Table 4-8. Comparison of ICRP and DCAL dose coefficients for 228Ac. Inhalation type F Inhalation type M Inhalation type S Ingestion: f1 = 0.0005

ICRP DCAL Ratio ICRP DCAL Ratio ICRP DCAL Ratio ICRP DCAL Ratio

Adrenals 4.5E-11 4.56E-11 0.99 1.8E-11 1.86E-11 0.97 1.4E-11 1.36E-11 1.03 1.9E-11 1.94E-11 0.98

Bladder wall 3.7E-11 3.72E-11 0.99 1.9E-11 1.95E-11 0.97 1.7E-11 1.67E-11 1.02 4.1E-11 4.11E-11 1.00

Bone surface 8.4E-07 8.44E-07 1.00 1.7E-07 1.72E-07 0.99 7.9E-09 7.92E-09 1.00 1.5E-09 1.51E-09 0.99

Brain 2.2E-11 2.26E-11 0.97 1.1E-11 1.11E-11 0.99 8.9E-12 8.91E-12 1.00 1.6E-13 1.55E-13 1.04

Breast 1.8E-11 1.86E-11 0.97 1.0E-11 1.03E-11 0.97 9.4E-12 9.43E-12 1.00 4.3E-12 4.28E-12 1.00

St wall 1.4E-10 1.43E-10 0.98 2.4E-10 2.40E-10 1.00 2.5E-10 2.50E-10 1.00 6.1E-10 6.17E-10 0.99

Si wall 2.3E-10 2.29E-10 1.00 4.0E-10 4.01E-10 1.00 4.2E-10 4.18E-10 1.00 1.0E-09 1.05E-09 0.96

ULI wall 5.2E-10 5.27E-10 0.99 9.2E-10 9.24E-10 1.00 9.6E-10 9.67E-10 0.99 2.4E-09 2.41E-09 0.99

LLI wall 4.1E-10 4.08E-10 1.01 7.1E-10 7.17E-10 0.99 7.5E-10 7.52E-10 1.00 1.9E-09 1.87E-09 1.02

Kidneys 3.8E-11 3.82E-11 0.99 2.1E-11 2.10E-11 1.00 1.7E-11 1.73E-11 0.98 3.7E-11 3.73E-11 0.99

Liver 2.2E-07 2.23E-07 0.99 4.5E-08 4.55E-08 0.99 2.1E-09 2.11E-09 1.00 4.2E-10 4.23E-10 0.99

Muscle 2.8E-11 2.87E-11 0.98 1.9E-11 1.94E-11 0.98 1.8E-11 1.76E-11 1.02 2.2E-11 2.22E-11 0.99

Ovaries 9.2E-09 9.40E-09 0.98 1.9E-09 1.97E-09 0.96 1.5E-10 1.51E-10 0.99 1.7E-10 1.74E-10 0.98

Pancreas 4.3E-11 4.32E-11 1.00 2.6E-11 2.65E-11 0.98 2.3E-11 2.30E-11 1.00 4.6E-11 4.65E-11 0.99

Red marrow 6.7E-08 6.76E-08 0.99 1.4E-08 1.38E-08 1.01 6.5E-10 6.54E-10 0.99 1.5E-10 1.52E-10 0.98

ET1 8.1E-07 8.30E-07 0.98 8.1E-07 8.30E-07 0.98 8.1E-07 8.30E-07 0.98 6.9E-13 6.72E-13 1.03

ET2 2.6E-09 2.65E-09 0.98 2.5E-08 2.48E-08 1.01 8.5E-08 8.56E-08 0.99 6.9E-13 6.72E-13 1.03

LNet 2.2E-09 2.24E-09 0.98 3.2E-09 3.22E-09 0.99 2.1E-08 2.16E-08 0.97 6.9E-13 6.72E-13 1.03

Lungs 6.4E-11 6.48E-11 0.99 4.9E-08 4.91E-08 1.00 8.0E-08 8.09E-08 0.99 6.4E-12 6.38E-12 1.00

LNth 3.0E-11 3.03E-11 0.99 4.7E-09 4.78E-09 0.98 5.3E-08 5.44E-08 0.97 6.4E-12 6.38E-12 1.00

Skin 1.8E-11 1.81E-11 1.00 9.3E-12 9.34E-12 1.00 7.7E-12 7.66E-12 1.00 8.5E-12 8.48E-12 1.00

Spleen 2.4E-11 2.45E-11 0.98 1.8E-11 1.79E-11 1.00 1.7E-11 1.68E-11 1.01 3.1E-11 3.13E-11 0.99

Testes 9.2E-09 9.37E-09 0.98 1.9E-09 1.91E-09 0.99 9.1E-11 9.22E-11 0.99 2.7E-11 2.75E-11 0.98

Thymus 2.7E-11 2.67E-11 1.01 1.8E-11 1.77E-11 1.02 1.7E-11 1.69E-11 1.01 3.1E-12 3.07E-12 1.01

Thyroid 2.2E-11 2.26E-11 0.97 1.2E-11 1.24E-11 0.97 1.1E-11 1.08E-11 1.02 6.9E-13 6.72E-13 1.03

Uterus 3.6E-11 3.59E-11 1.00 3.7E-11 3.77E-11 0.98 3.7E-11 3.69E-11 1.00 9.0E-11 9.13E-11 0.99

Effective dose 2.9E-08 2.97E-08 0.98 1.2E-08 1.21E-08 0.99 1.2E-08 1.23E-08 0.98 4.3E-10 4.30E-10 1.00
Document No. ORAUT-OTIB-0028 Revision No. 02 Effective Date: 07/28/2008 Page 17 of 22

Table 4-9. Comparison of ICRP and DCAL dose coefficients for 232U. Inhalation type F Inhalation type M Inhalation type S Ingestion: f1 = 0.02 Ingestion: f1 = 0.002

ICRP DCAL Ratio ICRP DCAL Ratio ICRP DCAL Ratio ICRP DCAL Ratio ICRP DCAL Ratio

Adrenals 2.3E-06 2.34E-06 0.98 6.1E-07 6.29E-07 0.97 1.0E-07 1.06E-07 0.95 1.6E-07 1.64E-07 0.97 1.6E-08 1.64E-08 0.97

Bladder wall 2.3E-06 2.34E-06 0.98 6.1E-07 6.29E-07 0.97 9.7E-08 9.99E-08 0.97 1.6E-07 1.64E-07 0.97 1.6E-08 1.64E-08 0.97

Bone surface 1.0E-04 1.03E-04 0.97 4.6E-05 4.64E-05 0.99 2.0E-05 2.01E-05 1.00 7.2E-06 7.21E-06 1.00 7.2E-07 7.21E-07 1.00

Brain 2.3E-06 2.34E-06 0.98 6.1E-07 6.28E-07 0.97 9.7E-08 9.99E-08 0.97 1.6E-07 1.64E-07 0.98 1.6E-08 1.64E-08 0.98

Breast 2.3E-06 2.34E-06 0.98 6.1E-07 6.27E-07 0.97 1.0E-07 1.06E-07 0.95 1.6E-07 1.64E-07 0.98 1.6E-08 1.64E-08 0.98

St wall 2.3E-06 2.34E-06 0.98 6.1E-07 6.28E-07 0.97 1.0E-07 1.03E-07 0.97 1.6E-07 1.65E-07 0.97 1.7E-08 1.76E-08 0.96

Si wall 2.3E-06 2.34E-06 0.98 6.1E-07 6.29E-07 0.97 9.9E-08 1.02E-07 0.97 1.6E-07 1.67E-07 0.96 1.9E-08 1.95E-08 0.97

ULI wall 2.3E-06 2.40E-06 0.96 6.5E-07 6.73E-07 0.97 1.3E-07 1.32E-07 0.99 1.8E-07 1.87E-07 0.96 3.5E-08 3.57E-08 0.98

LLI wall 2.4E-06 2.52E-06 0.95 7.4E-07 7.61E-07 0.97 1.9E-07 1.92E-07 0.99 2.2E-07 2.30E-07 0.96 7.2E-08 7.30E-08 0.99

Kidneys 9.5E-06 9.73E-06 0.98 2.9E-06 2.93E-06 0.99 6.8E-07 6.95E-07 0.98 6.7E-07 6.83E-07 0.98 6.7E-08 6.83E-08 0.98

Liver 1.0E-05 1.03E-05 0.98 3.3E-06 3.39E-06 0.97 9.6E-07 9.79E-07 0.98 7.0E-07 7.19E-07 0.97 7.0E-08 7.20E-08 0.97

Muscle 2.3E-06 2.34E-06 0.98 6.1E-07 6.28E-07 0.97 9.9E-08 1.02E-07 0.97 1.6E-07 1.64E-07 0.98 1.6E-08 1.64E-08 0.98

Ovaries 2.4E-06 2.58E-06 0.93 7.7E-07 8.18E-07 0.94 2.1E-07 2.14E-07 0.98 1.7E-07 1.81E-07 0.94 1.7E-08 1.81E-08 0.94

Pancreas 2.3E-06 2.34E-06 0.98 6.1E-07 6.28E-07 0.97 1.0E-07 1.04E-07 0.96 1.6E-07 1.64E-07 0.98 1.6E-08 1.64E-08 0.98

Red marrow 9.9E-06 1.01E-05 0.99 4.1E-06 4.13E-06 0.99 1.6E-06 1.63E-06 0.98 7.0E-07 7.05E-07 0.99 7.0E-08 7.06E-08 0.99

ET1 9.7E-06 1.01E-05 0.96 8.0E-06 8.37E-06 0.96 7.6E-06 7.89E-06 0.96 1.6E-07 1.64E-07 0.98 1.6E-08 1.64E-08 0.98

ET2 2.3E-06 2.34E-06 0.98 2.4E-05 2.32E-05 1.03 2.8E-04 0.000267 1.05 1.6E-07 1.64E-07 0.98 1.6E-08 1.64E-08 0.98

LNet 2.3E-06 2.34E-06 0.98 2.2E-06 2.17E-06 1.02 8.2E-04 0.000799 1.03 1.6E-07 1.64E-07 0.98 1.6E-08 1.64E-08 0.98

Lungs 2.3E-06 2.35E-06 0.98 2.7E-05 2.68E-05 1.01 1.5E-04 0.000148 1.01 1.6E-07 1.64E-07 0.98 1.6E-08 1.64E-08 0.98

LNth 2.3E-06 2.34E-06 0.98 7.0E-06 6.94E-06 1.01 2.8E-03 0.002703 1.04 1.6E-07 1.64E-07 0.98 1.6E-08 1.64E-08 0.98

Skin 2.3E-06 2.34E-06 0.98 6.1E-07 6.27E-07 0.97 9.8E-08 1.01E-07 0.97 1.6E-07 1.64E-07 0.98 1.6E-08 1.64E-08 0.98

Spleen 2.2E-06 2.35E-06 0.94 6.0E-07 6.30E-07 0.95 9.9E-08 1.04E-07 0.95 1.6E-07 1.65E-07 0.97 1.6E-08 1.65E-08 0.97

Testes 2.4E-06 2.58E-06 0.93 7.8E-07 8.21E-07 0.95 2.1E-07 2.15E-07 0.98 1.7E-07 1.81E-07 0.94 1.7E-08 1.81E-08 0.94

Thymus 2.3E-06 2.34E-06 0.98 6.1E-07 6.27E-07 0.97 1.0E-07 1.07E-07 0.94 1.6E-07 1.64E-07 0.98 1.6E-08 1.64E-08 0.98

Thyroid 2.3E-06 2.34E-06 0.98 6.1E-07 6.27E-07 0.97 9.9E-08 1.02E-07 0.97 1.6E-07 1.64E-07 0.98 1.6E-08 1.64E-08 0.98

Uterus 2.3E-06 2.34E-06 0.98 6.1E-07 6.28E-07 0.97 9.7E-08 9.96E-08 0.97 1.6E-07 1.64E-07 0.98 1.6E-08 1.64E-08 0.98

Effective dose 4.7E-06 4.73E-06 0.99 4.8E-06 4.83E-06 0.99 2.6E-05 2.50E-05 1.04 3.3E-07 3.36E-07 0.98 3.7E-08 3.75E-08 0.99
Document No. ORAUT-OTIB-0028 Revision No. 02 Effective Date: 07/28/2008 Page 18 of 22

Table 4-10. Comparison of ICRP and DCAL dose coefficients for 233U. Inhalation type F Inhalation type M Inhalation type S Ingestion: f1 = 0.02 Ingestion: f1 = 0.002

ICRP DCAL Ratio ICRP DCAL Ratio ICRP DCAL Ratio ICRP DCAL Ratio ICRP DCAL Ratio

Adrenals 4.0E-07 4.05E-07 0.99 9.7E-08 9.89E-08 0.98 9.3E-09 9.52E-09 0.98 2.8E-08 2.84E-08 0.99 2.8E-09 2.84E-09 0.99

Bladder wall 4.0E-07 4.06E-07 0.98 9.7E-08 9.93E-08 0.98 9.4E-09 9.55E-09 0.98 2.8E-08 2.85E-08 0.98 2.8E-09 2.85E-09 0.98

Bone surface 1.2E-05 1.20E-05 1.00 3.0E-06 2.98E-06 1.01 4.2E-07 4.20E-07 1.00 8.3E-07 8.38E-07 0.99 8.3E-08 8.38E-08 0.99

Brain 4.0E-07 4.05E-07 0.99 9.7E-08 9.89E-08 0.98 9.3E-09 9.51E-09 0.98 2.8E-08 2.84E-08 0.99 2.8E-09 2.84E-09 0.99

Breast 4.0E-07 4.05E-07 0.99 9.7E-08 9.89E-08 0.98 9.3E-09 9.52E-09 0.98 2.8E-08 2.84E-08 0.99 2.8E-09 2.84E-09 0.99

St wall 4.0E-07 4.05E-07 0.99 9.7E-08 9.94E-08 0.98 9.9E-09 1.01E-08 0.99 2.9E-08 2.95E-08 0.98 3.9E-09 3.96E-09 0.99

Si wall 4.0E-07 4.05E-07 0.99 9.8E-08 1.00E-07 0.98 1.1E-08 1.08E-08 1.01 3.1E-08 3.11E-08 1.00 5.6E-09 5.63E-09 0.99

ULI wall 4.0E-07 4.08E-07 0.98 1.0E-07 1.06E-07 0.94 1.7E-08 1.76E-08 0.97 4.4E-08 4.50E-08 0.98 2.0E-08 1.98E-08 1.01

LLI wall 4.1E-07 4.15E-07 0.99 1.2E-07 1.20E-07 1.00 3.3E-08 3.31E-08 1.00 7.6E-08 7.72E-08 0.99 5.2E-08 5.25E-08 0.99

Kidneys 4.1E-06 4.15E-06 0.99 1.0E-06 1.02E-06 0.98 1.1E-07 1.07E-07 1.03 2.9E-07 2.91E-07 1.00 2.9E-08 2.91E-08 1.00

Liver 1.5E-06 1.58E-06 0.95 3.8E-07 3.89E-07 0.98 4.4E-08 4.52E-08 0.97 1.1E-07 1.11E-07 0.99 1.1E-08 1.11E-08 0.99

Muscle 4.0E-07 4.05E-07 0.99 9.7E-08 9.89E-08 0.98 9.3E-09 9.52E-09 0.98 2.8E-08 2.84E-08 0.99 2.8E-09 2.84E-09 0.99

Ovaries 4.0E-07 4.07E-07 0.98 9.8E-08 9.99E-08 0.98 1.0E-08 1.04E-08 0.96 2.8E-08 2.86E-08 0.98 2.8E-09 2.86E-09 0.98

Pancreas 4.0E-07 4.05E-07 0.99 9.7E-08 9.89E-08 0.98 9.3E-09 9.52E-09 0.98 2.8E-08 2.84E-08 0.99 2.8E-09 2.84E-09 0.99

Red marrow 1.2E-06 1.20E-06 1.00 2.9E-07 2.96E-07 0.98 3.6E-08 3.63E-08 0.99 8.3E-08 8.40E-08 0.99 8.3E-09 8.40E-09 0.99

ET1 4.3E-07 4.17E-07 1.03 1.4E-07 1.11E-07 1.27 4.8E-08 2.19E-08 2.19 2.8E-08 2.84E-08 0.99 2.8E-09 2.84E-09 0.99

ET2 4.0E-07 4.06E-07 0.99 1.3E-05 1.27E-05 1.02 7.6E-05 7.64E-05 1.00 2.8E-08 2.84E-08 0.99 2.8E-09 2.84E-09 0.99

LNet 4.0E-07 4.05E-07 0.99 6.3E-07 6.41E-07 0.98 1.3E-04 1.37E-04 0.95 2.8E-08 2.84E-08 0.99 2.8E-09 2.84E-09 0.99

Lungs 4.1E-07 4.16E-07 0.98 1.7E-05 1.67E-05 1.02 4.2E-05 4.21E-05 1.00 2.8E-08 2.84E-08 0.99 2.8E-09 2.84E-09 0.99

LNth 4.0E-07 4.05E-07 0.99 2.6E-06 2.63E-06 0.99 4.6E-04 4.72E-04 0.97 2.8E-08 2.84E-08 0.99 2.8E-09 2.84E-09 0.99

Skin 4.0E-07 4.05E-07 0.99 9.7E-08 9.89E-08 0.98 9.3E-09 9.51E-09 0.98 2.8E-08 2.84E-08 0.99 2.8E-09 2.84E-09 0.99

Spleen 4.0E-07 4.05E-07 0.99 9.7E-08 9.90E-08 0.98 9.3E-09 9.52E-09 0.98 2.8E-08 2.84E-08 0.99 2.8E-09 2.84E-09 0.99

Testes 4.0E-07 4.07E-07 0.98 9.8E-08 9.99E-08 0.98 1.0E-08 1.04E-08 0.96 2.8E-08 2.86E-08 0.98 2.8E-09 2.86E-09 0.98

Thymus 4.0E-07 4.05E-07 0.99 9.7E-08 9.89E-08 0.98 9.3E-09 9.52E-09 0.98 2.8E-08 2.84E-08 0.99 2.8E-09 2.84E-09 0.99

Thyroid 4.0E-07 4.05E-07 0.99 9.7E-08 9.89E-08 0.98 9.3E-09 9.51E-09 0.98 2.8E-08 2.84E-08 0.99 2.8E-09 2.84E-09 0.99

Uterus 4.0E-07 4.05E-07 0.99 9.7E-08 9.89E-08 0.98 9.3E-09 9.51E-09 0.98 2.8E-08 2.84E-08 0.99 2.8E-09 2.84E-09 0.99

Effective dose 6.6E-07 6.79E-07 0.97 2.2E-06 2.16E-06 1.02 6.9E-06 6.98E-06 0.99 5.0E-08 5.13E-08 0.98 8.5E-09 8.61E-09 0.99
Document No. ORAUT-OTIB-0028 Revision No. 02 Effective Date: 07/28/2008 Page 19 of 22

Table 4-11. Comparison of ICRP and DCAL dose coefficients for 239U. Inhalation type F Inhalation type M Inhalation type S Ingestion: f1 = 0.02 Ingestion: f1 = 0.002

ICRP DCAL Ratio ICRP DCAL Ratio ICRP DCAL Ratio ICRP DCAL Ratio ICRP DCAL Ratio

Adrenals 5.1E-13 5.11E-13 1.00 1.7E-13 1.74E-13 0.98 1.3E-13 1.34E-13 0.97 2.4E-13 2.38E-13 1.01 2.3E-13 2.31E-13 1.00

Bladder wall 2.2E-11 2.22E-11 0.99 2.4E-12 2.43E-12 0.99 1.8E-13 1.85E-13 0.97 5.9E-13 5.93E-13 1.00 4.1E-13 4.16E-13 0.99

Bone surface 5.6E-12 5.68E-12 0.99 9.4E-13 9.56E-13 0.98 2.8E-13 2.99E-13 0.94 5.7E-13 5.81E-13 0.98 2.9E-13 2.96E-13 0.98

Brain 4.5E-13 4.51E-13 1.00 1.1E-13 1.13E-13 0.98 7.5E-14 7.33E-14 1.02 5.3E-15 5.34E-15 0.99 8.1E-16 8.00E-16 1.01

Breast 4.0E-13 4.00E-13 1.00 1.2E-13 1.15E-13 1.04 8.3E-14 8.25E-14 1.01 4.2E-14 4.07E-14 1.03 3.8E-14 3.66E-14 1.04

St wall 3.0E-11 2.96E-11 1.01 4.8E-11 4.81E-11 1.00 5.0E-11 5.01E-11 1.00 1.8E-10 1.76E-10 1.02 1.8E-10 1.76E-10 1.02

Si wall 1.0E-11 1.04E-11 0.96 1.7E-11 1.68E-11 1.01 1.8E-11 1.76E-11 1.02 5.9E-11 5.94E-11 0.99 5.9E-11 5.96E-11 0.99

ULI wall 8.2E-12 8.22E-12 1.00 1.4E-11 1.44E-11 0.97 1.5E-11 1.53E-11 0.98 4.1E-11 4.08E-11 1.01 4.1E-11 4.13E-11 0.99

LLI wall 1.3E-11 1.26E-11 1.03 2.4E-11 2.39E-11 1.00 2.6E-11 2.56E-11 1.02 6.1E-11 6.09E-11 1.00 6.2E-11 6.19E-11 1.00

Kidneys 1.2E-11 1.19E-11 1.01 1.5E-12 1.53E-12 0.98 1.7E-13 1.69E-13 1.01 8.7E-13 8.75E-13 0.99 4.0E-13 4.01E-13 1.00

Liver 6.1E-13 6.15E-13 0.99 1.8E-13 1.80E-13 1.00 1.3E-13 1.26E-13 1.03 2.2E-13 2.21E-13 1.00 2.1E-13 2.08E-13 1.01

Muscle 5.1E-13 5.12E-13 1.00 2.1E-13 2.13E-13 0.98 1.8E-13 1.79E-13 1.00 2.1E-13 2.15E-13 0.98 2.1E-13 2.12E-13 0.99

Ovaries 6.9E-13 6.92E-13 1.00 5.4E-13 5.45E-13 0.99 5.3E-13 5.34E-13 0.99 1.4E-12 1.38E-12 1.02 1.4E-12 1.39E-12 1.01

Pancreas 6.0E-13 6.09E-13 0.99 3.5E-13 3.65E-13 0.96 3.2E-13 3.36E-13 0.95 9.3E-13 9.72E-13 0.96 9.2E-13 9.66E-13 0.95

Red marrow 1.3E-12 1.33E-12 0.98 3.0E-13 3.02E-13 0.99 1.7E-13 1.71E-13 0.99 3.0E-13 3.04E-13 0.99 2.7E-13 2.67E-13 1.01

ET1 6.0E-08 5.99E-08 1.00 6.0E-08 5.99E-08 1.00 6.0E-08 5.99E-08 1.00 7.3E-15 7.17E-15 1.02 2.7E-15 2.62E-15 1.03

ET2 3.2E-10 3.22E-10 0.99 5.1E-10 5.12E-10 1.00 5.3E-10 5.34E-10 0.99 7.3E-15 7.17E-15 1.02 2.7E-15 2.62E-15 1.03

LNet 3.3E-11 3.42E-11 0.97 3.5E-11 3.63E-11 0.96 3.5E-11 3.68E-11 0.95 7.3E-15 7.17E-15 1.02 2.7E-15 2.62E-15 1.03

Lungs 2.0E-11 1.97E-11 1.02 9.1E-11 9.14E-11 1.00 1.0E-10 9.98E-11 1.00 8.5E-14 8.57E-14 0.99 8.0E-14 8.09E-14 0.99

LNth 4.9E-13 4.97E-13 0.99 5.2E-13 5.29E-13 0.98 1.4E-12 1.45E-12 0.96 8.5E-14 8.57E-14 0.99 8.0E-14 8.09E-14 0.99

Skin 4.1E-13 4.11E-13 1.00 9.4E-14 9.47E-14 0.99 5.8E-14 5.83E-14 1.00 6.6E-14 6.56E-14 1.01 6.2E-14 6.19E-14 1.00

Spleen 5.4E-13 5.51E-13 0.98 2.6E-13 2.62E-13 0.99 2.2E-13 2.28E-13 0.96 5.9E-13 6.09E-13 0.97 5.8E-13 6.03E-13 0.96

Testes 4.1E-13 4.12E-13 1.00 7.5E-14 7.49E-14 1.00 3.7E-14 3.64E-14 1.02 9.3E-14 9.20E-14 1.01 9.0E-14 8.88E-14 1.01

Thymus 4.8E-13 4.78E-13 1.00 2.0E-13 1.97E-13 1.02 1.7E-13 1.65E-13 1.03 2.8E-14 2.64E-14 1.06 2.3E-14 2.19E-14 1.05

Thyroid 4.5E-13 4.55E-13 0.99 1.3E-13 1.30E-13 1.00 9.4E-14 9.22E-14 1.02 7.3E-15 7.17E-15 1.02 2.7E-15 2.62E-15 1.03

Uterus 6.0E-13 6.05E-13 0.99 3.1E-13 3.20E-13 0.97 2.8E-13 2.89E-13 0.97 7.7E-13 7.83E-13 0.98 7.7E-13 7.85E-13 0.98

Effective dose 1.8E-11 1.83E-11 0.99 3.3E-11 3.36E-11 0.98 3.5E-11 3.54E-11 0.99 2.7E-11 2.76E-11 0.98 2.8E-11 2.76E-11 1.01
Document No. ORAUT-OTIB-0028 Revision No. 02 Effective Date: 07/28/2008 Page 20 of 22

Table 4-12. Comparison of ICRP and DCAL dose coefficients for 228Th. Inhalation type M Inhalation type S Ingestion: f1 = 0.0005 Ingestion: f1 = 0.0002

ICRP DCAL Ratio ICRP DCAL Ratio ICRP DCAL Ratio ICRP DCAL Ratio

Adrenals 7.7E-07 7.74E-07 0.99 3.7E-08 3.79E-08 0.98 7.1E-09 7.13E-09 1.00 3.1E-09 3.09E-09 1.00

Bladder wall 7.8E-07 7.78E-07 1.00 3.4E-08 3.47E-08 0.98 7.2E-09 7.24E-09 0.99 3.2E-09 3.17E-09 1.01

Bone surface 2.8E-04 2.81E-04 1.00 1.2E-05 1.23E-05 0.97 2.5E-06 2.52E-06 0.99 1.0E-06 1.05E-06 0.95

Brain 7.7E-07 7.71E-07 1.00 3.4E-08 3.45E-08 0.98 7.1E-09 7.10E-09 1.00 3.1E-09 3.07E-09 1.01

Breast 7.7E-07 7.71E-07 1.00 3.7E-08 3.80E-08 0.97 7.1E-09 7.10E-09 1.00 3.1E-09 3.07E-09 1.01

St wall 7.7E-07 7.72E-07 1.00 3.6E-08 3.71E-08 0.97 8.4E-09 8.44E-09 1.00 4.4E-09 4.41E-09 1.00

Si wall 7.8E-07 7.75E-07 1.01 3.7E-08 3.70E-08 1.00 1.1E-08 1.08E-08 1.02 6.7E-09 6.75E-09 0.99

ULI wall 1.1E-06 1.09E-06 1.01 6.5E-08 6.53E-08 1.00 4.0E-08 3.99E-08 1.00 3.4E-08 3.43E-08 0.99

LLI wall 1.7E-06 1.73E-06 0.98 1.4E-07 1.42E-07 0.98 1.5E-07 1.45E-07 1.03 1.4E-07 1.37E-07 1.02

Kidneys 7.3E-06 7.33E-06 1.00 3.2E-07 3.24E-07 0.99 6.5E-08 6.53E-08 1.00 2.7E-08 2.69E-08 1.00

Liver 1.2E-05 1.17E-05 1.03 5.1E-07 5.15E-07 0.99 1.0E-07 1.04E-07 0.96 4.3E-08 4.29E-08 1.00

Muscle 7.7E-07 7.71E-07 1.00 3.5E-08 3.58E-08 0.98 7.1E-09 7.13E-09 1.00 3.1E-09 3.10E-09 1.00

Ovaries 2.3E-06 2.34E-06 0.98 1.0E-07 1.03E-07 0.97 2.1E-08 2.10E-08 1.00 8.8E-09 8.76E-09 1.00

Pancreas 7.7E-07 7.72E-07 1.00 3.6E-08 3.69E-08 0.98 7.1E-09 7.13E-09 1.00 3.1E-09 3.09E-09 1.00

Red marrow 2.2E-05 2.16E-05 1.02 9.4E-07 9.53E-07 0.99 2.0E-07 1.95E-07 1.02 8.2E-08 8.19E-08 1.00

ET1 7.6E-04 7.57E-04 1.00 7.6E-04 7.56E-04 1.00 7.1E-09 7.10E-09 1.00 3.1E-09 3.07E-09 1.01

ET2 5.7E-05 5.73E-05 1.00 2.1E-04 2.14E-04 0.98 7.1E-09 7.10E-09 1.00 3.1E-09 3.07E-09 1.01

LNet 3.2E-06 3.22E-06 0.99 5.0E-05 4.99E-05 1.00 7.1E-09 7.10E-09 1.00 3.1E-09 3.07E-09 1.01

Lungs 1.3E-04 1.27E-04 1.03 2.1E-04 2.08E-04 1.01 7.1E-09 7.11E-09 1.00 3.1E-09 3.08E-09 1.01

LNth 1.3E-05 1.31E-05 1.00 1.4E-04 1.41E-04 1.00 7.1E-09 7.11E-09 1.00 3.1E-09 3.08E-09 1.01

Skin 7.7E-07 7.70E-07 1.00 3.4E-08 3.50E-08 0.97 7.1E-09 7.10E-09 1.00 3.1E-09 3.08E-09 1.01

Spleen 7.7E-07 7.73E-07 1.00 3.6E-08 3.69E-08 0.98 7.1E-09 7.13E-09 1.00 3.1E-09 3.09E-09 1.00

Testes 2.4E-06 2.37E-06 1.01 1.0E-07 1.04E-07 0.96 2.1E-08 2.11E-08 1.00 8.7E-09 8.67E-09 1.00

Thymus 7.7E-07 7.71E-07 1.00 3.8E-08 3.87E-08 0.98 7.1E-09 7.10E-09 1.00 3.1E-09 3.07E-09 1.01

Thyroid 7.7E-07 7.71E-07 1.00 3.5E-08 3.58E-08 0.98 7.1E-09 7.10E-09 1.00 3.1E-09 3.07E-09 1.01

Uterus 7.7E-07 7.72E-07 1.00 3.4E-08 3.45E-08 0.99 7.2E-09 7.19E-09 1.00 3.2E-09 3.16E-09 1.01

Effective dose 2.2E-05 2.21E-05 0.99 2.5E-05 2.53E-05 0.99 7.2E-08 7.20E-08 1.00 3.5E-08 3.54E-08 0.99
Document No. ORAUT-OTIB-0028 Revision No. 02 Effective Date: 07/28/2008 Page 21 of 22

Table 4-13. Comparison of ICRP and DCAL dose coefficients for 232Th. Inhalation type M Inhalation type S Ingestion: f1 = 0.0005 Ingestion: f1 = 0.0002

ICRP DCAL Ratio ICRP DCAL Ratio ICRP DCAL Ratio ICRP DCAL Ratio

Adrenals 4.4E-06 4.37E-06 1.01 4.1E-07 4.12E-07 0.99 3.6E-08 3.57E-08 1.01 1.4E-08 1.43E-08 0.98

Bladder wall 4.4E-06 4.36E-06 1.01 4.0E-07 4.05E-07 0.99 3.6E-08 3.56E-08 1.01 1.4E-08 1.42E-08 0.98

Bone surface 1.5E-03 1.45E-03 1.03 1.4E-04 1.42E-04 0.99 1.2E-05 1.18E-05 1.02 4.7E-06 4.73E-06 0.99

Brain 4.4E-06 4.37E-06 1.01 4.0E-07 4.06E-07 0.99 3.6E-08 3.56E-08 1.01 1.4E-08 1.43E-08 0.98

Breast 4.4E-06 4.36E-06 1.01 4.1E-07 4.11E-07 1.00 3.6E-08 3.55E-08 1.01 1.4E-08 1.42E-08 0.98

St wall 4.4E-06 4.36E-06 1.01 4.1E-07 4.08E-07 1.00 3.6E-08 3.65E-08 0.99 1.5E-08 1.52E-08 0.99

Si wall 4.4E-06 4.36E-06 1.01 4.1E-07 4.07E-07 1.01 3.8E-08 3.80E-08 1.00 1.7E-08 1.66E-08 1.02

ULI wall 4.5E-06 4.45E-06 1.01 4.3E-07 4.31E-07 1.00 5.0E-08 5.05E-08 0.99 2.9E-08 2.87E-08 1.01

LLI wall 4.6E-06 4.64E-06 0.99 4.8E-07 4.80E-07 1.00 7.9E-08 7.93E-08 1.00 5.7E-08 5.67E-08 1.00

Kidneys 2.3E-05 2.26E-05 1.02 2.4E-06 2.36E-06 1.02 1.8E-07 1.84E-07 0.98 7.4E-08 7.36E-08 1.01

Liver 2.3E-05 2.28E-05 1.01 2.5E-06 2.51E-06 1.00 1.9E-07 1.85E-07 1.03 7.4E-08 7.41E-08 1.00

Muscle 4.4E-06 4.36E-06 1.01 4.1E-07 4.08E-07 1.01 3.6E-08 3.56E-08 1.01 1.4E-08 1.43E-08 0.98

Ovaries 1.3E-05 1.32E-05 0.98 1.3E-06 1.28E-06 1.02 1.1E-07 1.08E-07 1.02 4.3E-08 4.30E-08 1.00

Pancreas 4.4E-06 4.36E-06 1.01 4.1E-07 4.09E-07 1.00 3.6E-08 3.56E-08 1.01 1.4E-08 1.43E-08 0.98

Red marrow 5.7E-05 5.74E-05 0.99 6.1E-06 6.16E-06 0.99 4.7E-07 4.67E-07 1.01 1.9E-07 1.87E-07 1.02

ET1 4.4E-06 4.37E-06 1.01 4.7E-07 4.75E-07 0.99 3.6E-08 3.56E-08 1.01 1.4E-08 1.42E-08 0.98

ET2 1.5E-05 1.48E-05 1.01 1.1E-04 1.05E-04 1.05 3.6E-08 3.56E-08 1.01 1.4E-08 1.42E-08 0.98

LNet 4.9E-06 4.89E-06 1.00 7.1E-04 7.09E-04 1.00 3.6E-08 3.56E-08 1.01 1.4E-08 1.42E-08 0.98

Lungs 1.6E-05 1.58E-05 1.01 7.7E-05 7.73E-05 1.00 3.6E-08 3.56E-08 1.01 1.4E-08 1.42E-08 0.98

LNth 6.7E-06 6.71E-06 1.00 2.6E-03 2.61E-03 1.00 3.6E-08 3.56E-08 1.01 1.4E-08 1.42E-08 0.98

Skin 4.4E-06 4.36E-06 1.01 4.0E-07 4.06E-07 0.99 3.6E-08 3.56E-08 1.01 1.4E-08 1.42E-08 0.98

Spleen 4.4E-06 4.37E-06 1.01 4.1E-07 4.10E-07 1.00 3.6E-08 3.56E-08 1.01 1.4E-08 1.43E-08 0.98

Testes 1.3E-05 1.34E-05 0.97 1.3E-06 1.30E-06 1.00 1.1E-07 1.09E-07 1.01 4.4E-08 4.36E-08 1.01

Thymus 4.4E-06 4.36E-06 1.01 4.1E-07 4.13E-07 0.99 3.6E-08 3.56E-08 1.01 1.4E-08 1.42E-08 0.98

Thyroid 4.4E-06 4.36E-06 1.01 4.1E-07 4.08E-07 1.01 3.6E-08 3.56E-08 1.01 1.4E-08 1.42E-08 0.98

Uterus 4.4E-06 4.36E-06 1.01 4.0E-07 4.05E-07 0.99 3.6E-08 3.56E-08 1.01 1.4E-08 1.42E-08 0.98

Effective dose 2.9E-05 2.93E-05 0.99 1.2E-05 1.20E-05 1.00 2.2E-07 2.31E-07 0.95 9.2E-08 9.42E-08 0.98
Document No. ORAUT-OTIB-0028 Revision No. 02 Effective Date: 07/28/2008 Page 22 of 22

Table 4-14. Comparison of ICRP and DCAL dose coefficients for 234Th.

Inhalation type M Inhalation type S Ingestion: f1 = 0.0005 Ingestion: f1 = 0.0002

ICRP DCAL Ratio ICRP DCAL Ratio ICRP DCAL Ratio ICRP DCAL Ratio

Adrenals 5.3E-11 5.34E-11 0.99 8.1E-12 8.14E-12 1.00 2.1E-12 2.12E-12 0.99 1.7E-12 1.72E-12 0.99

Bladder wall 6.0E-11 5.99E-11 1.00 4.8E-12 4.90E-12 0.98 9.8E-12 9.92E-12 0.99 9.3E-12 9.45E-12 0.98

Bone surface 3.1E-09 3.09E-09 1.00 5.4E-11 5.46E-11 0.99 4.7E-11 4.72E-11 1.00 2.1E-11 2.11E-11 0.99

Brain 4.6E-11 4.66E-11 0.99 1.8E-12 1.78E-12 1.01 6.5E-13 6.50E-13 1.00 2.6E-13 2.65E-13 0.98

Breast 5.0E-11 5.07E-11 0.99 8.0E-12 8.08E-12 0.99 8.8E-13 8.83E-13 1.00 5.1E-13 5.05E-13 1.01

St wall 4.6E-10 4.62E-10 1.00 4.4E-10 4.42E-10 0.99 1.0E-09 9.99E-10 1.00 1.0E-09 9.98E-10 1.00

Si wall 1.1E-09 1.08E-09 1.02 1.1E-09 1.10E-09 1.00 2.5E-09 2.55E-09 0.98 2.5E-09 2.55E-09 0.98

ULI wall 6.2E-09 6.19E-09 1.00 6.5E-09 6.50E-09 1.00 1.5E-08 1.51E-08 0.99 1.5E-08 1.51E-08 0.99

LLI wall 1.7E-08 1.76E-08 0.97 1.8E-08 1.85E-08 0.97 4.3E-08 4.31E-08 1.00 4.3E-08 4.32E-08 1.00

Kidneys 1.1E-09 1.10E-09 1.00 2.1E-11 2.06E-11 1.02 1.9E-11 1.89E-11 1.00 9.6E-12 9.63E-12 1.00

Liver 4.0E-10 4.03E-10 0.99 1.3E-11 1.32E-11 0.98 7.9E-12 7.92E-12 1.00 4.5E-12 4.56E-12 0.99

Muscle 5.0E-11 4.99E-11 1.00 5.7E-12 5.83E-12 0.98 3.8E-12 3.87E-12 0.98 3.4E-12 3.49E-12 0.97

Ovaries 1.6E-10 1.61E-10 0.99 1.6E-11 1.59E-11 1.01 3.2E-11 3.30E-11 0.97 3.1E-11 3.18E-11 0.98

Pancreas 5.1E-11 5.15E-11 0.99 7.0E-12 7.06E-12 0.99 3.8E-12 3.78E-12 1.01 3.4E-12 3.39E-12 1.00

Red marrow 1.7E-09 1.72E-09 0.99 3.2E-11 3.23E-11 0.99 2.9E-11 2.91E-11 1.00 1.4E-11 1.46E-11 0.96

ET1 2.4E-06 2.34E-06 1.03 2.4E-06 2.34E-06 1.03 6.8E-13 6.81E-13 1.00 3.0E-13 2.98E-13 1.01

ET2 3.4E-09 3.47E-09 0.98 4.1E-09 4.15E-09 0.99 6.8E-13 6.81E-13 1.00 3.0E-13 2.98E-13 1.01

LNet 5.6E-10 5.71E-10 0.98 6.2E-10 6.29E-10 0.99 6.8E-13 6.81E-13 1.00 3.0E-13 2.98E-13 1.01

Lungs 3.0E-08 2.97E-08 1.01 3.7E-08 3.66E-08 1.01 1.0E-12 1.04E-12 0.96 6.6E-13 6.58E-13 1.00

LNth 6.3E-10 6.30E-10 1.00 9.7E-10 9.70E-10 1.00 1.0E-12 1.04E-12 0.96 6.6E-13 6.58E-13 1.00

Skin 4.6E-11 4.65E-11 0.99 2.7E-12 2.76E-12 0.98 1.7E-12 1.68E-12 1.01 1.3E-12 1.30E-12 1.00

Spleen 5.0E-11 5.05E-11 0.99 6.7E-12 6.74E-12 0.99 3.1E-12 3.08E-12 1.01 2.7E-12 2.69E-12 1.00

Testes 1.5E-10 1.51E-10 1.00 3.4E-12 3.43E-12 0.99 4.6E-12 4.63E-12 0.99 3.3E-12 3.37E-12 0.98

Thymus 5.3E-11 5.28E-11 1.00 1.0E-11 1.01E-11 0.99 8.2E-13 8.19E-13 1.00 4.4E-13 4.37E-13 1.01

Thyroid 4.8E-11 4.81E-11 1.00 4.0E-12 4.05E-12 0.99 6.8E-13 6.81E-13 1.00 3.0E-13 2.98E-13 1.01

Uterus 5.1E-11 5.10E-11 1.00 6.4E-12 6.47E-12 0.99 1.3E-11 1.35E-11 0.96 1.3E-11 1.32E-11 0.99

Effective dose 5.3E-09 5.26E-09 1.01 5.8E-09 5.85E-09 0.99 3.4E-09 3.40E-09 1.00 3.4E-09 3.40E-09 1.00